Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biomarin Pharmaceutical Inc Reaffirms FY 2013 Revenue Guidance; Raises Prior FY 2013 Earnings Guidance


Thursday, 25 Jul 2013 05:00pm EDT 

Biomarin Pharmaceutical Inc announced that for fiscal 2013, it expects total revenues in $530 million to $555 million range, expects GAAP loss forecast of $(185) to $(160) million and non-GAAP adjusted EBITDA $(65) to $(40) million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $545 million and net income of $(176) million for fiscal 2013. 

Company Quote

60.24
0.34 +0.57%
9 Jul 2014